Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.70 |
| ▸ | TTR | P02766 | 1/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137915 | 0.84 | AHR (1.00) | AHRCYP1B1HSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL29769221 | 0.84 | AHR (1.00) | AHRCYP1B1HSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL463718 | 0.84 | TTR (1.00) | AHRTTRCYP1B1HSD17B10ALDH1A1 | |
| SCHEMBL5487549 | 0.82 | HSD17B10 (0.67) | AHRTTRCYP1B1HSD17B10CYP3A4 | |
| SCHEMBL3566720 | 0.80 | TTR (0.70) | AHRTTRHSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL10540728 | 0.80 | AHR (0.70) | AHRCYP1B1HSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL7906570 | 0.80 | AHR (0.70) | AHRCYP1B1HSD17B10TSHRKMO | |
| SCHEMBL6335821 | 0.80 | AHR (0.70) | AHRCYP1B1HSD17B10ESR2MEN1 | |
| SCHEMBL8773697 | 0.79 | AHR (0.71) | AHRTTRCYP1B1HSD17B10ALDH1A1 | |
| Polychlorinated Biphenyl 126 SCHEMBL308662 | 0.79 | AHR (1.00) | AHRCYP1B1HSD17B10ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188743-B1 | TREATMENT OF HEPATIC AND CEREBRAL TOXICITY CAUSED BY AT LEAST ONE POLLUTANT | UNIV GRENOBLE ALPES (FR) | 2020-11-18 | — | — | EP | disclosed |
| EP-3188743-A1 | TREATMENT OF HEPATIC AND CEREBELLAR TOXICITY INDUCED BY AT LEAST ONE POLLUTANT | Université Joseph Fourier (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034828-A1 | TREATMENT OF HEPATIC AND CEREBELLAR TOXICITY INDUCED BY AT LEAST ONE POLLUTANT | UNIVERSITE JOSEPH FOURIER (FR) | 2016-03-10 | — | — | WO | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-13 | — | — | US | disclosed |
| EP-0802798-A1 | METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS | CHIRON CORPORATION (US) | 1997-10-29 | — | — | EP | disclosed |
| WO-1995022992-A1 | METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS | CHIRON CORPORATION (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | AHR 4301/4885TTR 1/4885CYP1B1 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.